Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors-Reference-Cited by-同舟云学术

Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

Published:2018-11-07 Issue:1 Volume:9 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Fassunke Jana,Müller Fabienne,Keul Marina,Michels Sebastian,Dammert Marcel A.,Schmitt Anna,Plenker Dennis^ORCID,Lategahn Jonas,Heydt Carina,Brägelmann Johannes,Tumbrink Hannah L.,Alber Yannic,Klein Sebastian,Heimsoeth Alena,Dahmen Ilona,Fischer Rieke N.,Scheffler Matthias,Ihle Michaela A.,Priesner Vanessa,Scheel Andreas H.^ORCID,Wagener Svenja,Kron Anna,Frank Konrad,Garbert Katia,Persigehl Thorsten,Püsken Michael,Haneder Stefan,Schaaf Bernhard,Rodermann Ernst,Engel-Riedel Walburga,Felip Enriqueta,Smit Egbert F.,Merkelbach-Bruse Sabine,Reinhardt H. Christian,Kast Stefan M.^ORCID,Wolf Jürgen,Rauh Daniel^ORCID,Büttner Reinhard,Sos Martin L.

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/s41467-018-07078-0.pdf

Reference61 articles.

1. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004).

2. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004).

3. Pao, W. et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101, 13306–13311 (2004).

4. Clinical Lung Cancer Genome Project (CLCGP); Network Genomic Medicine (NGM). A genomics-based classification of human lung tumors. Sci. Transl. Med. 5, 209ra153 (2013).

5. Maemondo, M. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380–2388 (2010).

Cited by 109 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fused in silico and bioactivity evaluation method for drug discovery: T001-10027877 was identified as an antiproliferative agent that targets EGFRT790M/C797S/L858R and EGFRT790M/L858R;BMC Chemistry;2024-08-27

2. Activity Alterations of 37 Tyrosine Kinase Inhibitors Upon kINPen Plasma Exposure in A549 Lung Cancer Cells;IEEE Transactions on Radiation and Plasma Medical Sciences;2024-07

3. Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms—An In Vitro Study;Biomedicines;2024-06-25

4. Integrated PBPK-EO modeling of osimertinib to predict plasma concentrations and intracranial EGFR engagement in patients with brain metastases;Scientific Reports;2024-06-03

5. New Treatment Options for Patients With Oncogene-Addicted Non–Small Cell Lung Cancer Focusing on EGFR-Mutant Tumors;American Society of Clinical Oncology Educational Book;2024-06